Aquestive Therapeutics, Inc. (AQST) Dividend History

Company News

• Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

  Aquestive Therapeutics announced positive pharmacokinetic results from a pediatric study for its Anaphylm product and completed the submission of its New Drug Application to the FDA.

  GlobeNewswire Inc.
• Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

  Aquestive Therapeutics announced new data on its investigational epinephrine sublingual film, Anaphylm, which demonstrated consistent stability, potency, and effective symptom resolution in treating severe allergic reactions, including anaphylaxis.

  GlobeNewswire Inc.
• Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

  WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024. The forum will include panels exploring key therapeutic themes across the fields of immunology and inflammation (I&I) and metabolism.

  GlobeNewswire Inc.
• Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

  WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film, the Company’s epinephrine prodrug product candidate that has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration (FDA). Sherry Korczynski joined the Aquestive leadership team as Senior Vice President, Sales and Marketing. Cassie Jung was promoted to Chief Operating Officer, and Stephen Wargacki, Ph.D., was named Chief Science Officer.

  GlobeNewswire Inc.
• 5 Small Drug Stocks to Buy From a Recovering Industry

  Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

  Zacks Investment Research

  Featured Companies: ACRV BVS CRDL HRTX